Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Cancer Chemotherapy and Pharmacology
|
November 16, 2014
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer
E Kontopodis, N Kentepozidis, Ch Christophyllakis, et al.
British Journal of Cancer
|
January 14, 2012
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
J Souglakos, N Ziras, S Kakolyris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
D Mavroudis, A Matikas, N Malamos, et al.
British Journal of Cancer
|
July 9, 2004
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study
V Georgoulias, C Kouroussis, A Agelidou, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 30, 2008
Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study
I Boukovinas, J Souglakos, D Hatzidaki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2007
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group
P A Kosmidis, H P Kalofonos, C Christodoulou, et al.
ESMO Open
|
September 19, 2024
Evaluation of the attributable fraction and burden of HPV-related oropharyngeal cancers in Greece-the ORPHEAS study
A Psyrri, G Psychogios, E Kyrodimos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 27, 2012
Adjuvant therapy in primary GIST: state-of-the-art
P Reichardt, J-Y Blay, I Boukovinas, et al.
ESMO Open
|
September 12, 2025
Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe
A Kyriazoglou, A Zając, C Valverde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 23, 2019
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project
J Souglakos, I Boukovinas, S Kakolyris, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Cancer Chemotherapy and Pharmacology
|
November 16, 2014
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer
E Kontopodis, N Kentepozidis, Ch Christophyllakis, et al.
British Journal of Cancer
|
January 14, 2012
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
J Souglakos, N Ziras, S Kakolyris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
D Mavroudis, A Matikas, N Malamos, et al.
British Journal of Cancer
|
July 9, 2004
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study
V Georgoulias, C Kouroussis, A Agelidou, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 30, 2008
Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study
I Boukovinas, J Souglakos, D Hatzidaki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2007
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group
P A Kosmidis, H P Kalofonos, C Christodoulou, et al.
ESMO Open
|
September 19, 2024
Evaluation of the attributable fraction and burden of HPV-related oropharyngeal cancers in Greece-the ORPHEAS study
A Psyrri, G Psychogios, E Kyrodimos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 27, 2012
Adjuvant therapy in primary GIST: state-of-the-art
P Reichardt, J-Y Blay, I Boukovinas, et al.
ESMO Open
|
September 12, 2025
Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe
A Kyriazoglou, A Zając, C Valverde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 23, 2019
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project
J Souglakos, I Boukovinas, S Kakolyris, et al.
Page
of 3